JP2013504623A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504623A5
JP2013504623A5 JP2012529823A JP2012529823A JP2013504623A5 JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5 JP 2012529823 A JP2012529823 A JP 2012529823A JP 2012529823 A JP2012529823 A JP 2012529823A JP 2013504623 A5 JP2013504623 A5 JP 2013504623A5
Authority
JP
Japan
Prior art keywords
yeast
based immunotherapy
agent
subject
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529823A
Other languages
English (en)
Japanese (ja)
Other versions
JP5913103B2 (ja
JP2013504623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/048699 external-priority patent/WO2011032119A1/en
Publication of JP2013504623A publication Critical patent/JP2013504623A/ja
Publication of JP2013504623A5 publication Critical patent/JP2013504623A5/ja
Application granted granted Critical
Publication of JP5913103B2 publication Critical patent/JP5913103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012529823A 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 Active JP5913103B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24235509P 2009-09-14 2009-09-14
US24235309P 2009-09-14 2009-09-14
US61/242,355 2009-09-14
US61/242,353 2009-09-14
US28856809P 2009-12-21 2009-12-21
US61/288,568 2009-12-21
PCT/US2010/048699 WO2011032119A1 (en) 2009-09-14 2010-09-14 Modulation of yeast-based immunotherapy products and responses

Publications (3)

Publication Number Publication Date
JP2013504623A JP2013504623A (ja) 2013-02-07
JP2013504623A5 true JP2013504623A5 (enExample) 2013-11-07
JP5913103B2 JP5913103B2 (ja) 2016-04-27

Family

ID=43034390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529823A Active JP5913103B2 (ja) 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法

Country Status (6)

Country Link
US (3) US8911722B2 (enExample)
EP (1) EP2477647B1 (enExample)
JP (1) JP5913103B2 (enExample)
AU (1) AU2010291985B2 (enExample)
CA (1) CA2774326C (enExample)
WO (1) WO2011032119A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
BR112013032381B1 (pt) * 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
RU2017143985A (ru) 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US11105802B2 (en) * 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
KR102409372B1 (ko) 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
US10857228B2 (en) * 2015-06-10 2020-12-08 The University Of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
WO2017044979A2 (en) * 2015-09-11 2017-03-16 Ventria Bioscience Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US20220323521A1 (en) * 2019-08-26 2022-10-13 The Brigham And Women`S Hospital, Inc. Compositions and Uses for Engineered Therapeutic Microbes and Associated Receptors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
EP0721341A4 (en) 1993-08-06 1998-04-22 Cytel Corp CLONING AND DESCRIPTION OF FULL MAGE-1 GENE CHARACTERISTICS
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2260078T3 (es) 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
RU2006135119A (ru) 2004-03-05 2008-04-10 Аркемикс Корп. (Us) Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP2009510093A (ja) 2005-09-28 2009-03-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆアンタゴニストならびにその使用方法
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
JP5322653B2 (ja) 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
EP1954719A2 (en) 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
MX2008009929A (es) 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
CN101448848B (zh) 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
CA2652599C (en) 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
US7846443B2 (en) * 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
WO2008025032A1 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Soluble il-27 receptor
US20100008917A1 (en) 2006-08-25 2010-01-14 Nancy Hosken Treatment of aplastic anemia
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CA2671697A1 (en) 2006-12-07 2008-06-12 Schering Corporation Use of il-27 agonists to reduce immune mediated abortion
JP2010512734A (ja) 2006-12-13 2010-04-30 アブリンクス エン．ヴェー． Ｉｌ−６／ｉｌ−６受容体複合体等受容体介在性シグナル伝達に関与する複合体に特異的なポリペプチド
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009047360A1 (en) 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2096438A1 (en) * 2008-02-28 2009-09-02 Martin Thurnher Methods for prognosing the status of patients
WO2009132821A1 (en) 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
AR072136A1 (es) 2008-05-23 2010-08-11 Wyeth Corp Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
JP2013522302A (ja) 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection

Similar Documents

Publication Publication Date Title
JP2013504623A5 (enExample)
Winheim et al. Impaired function and delayed regeneration of dendritic cells in COVID-19
Hussain et al. Similar but different: virtual memory CD8 T cells as a memory‐like cell population
Simons et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen
Wesa et al. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
Loebbermann et al. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells
Perreau et al. Lack of Mycobacterium tuberculosis–specific interleukin‐17A–producing CD4+ T cells in active disease
Jost et al. Changes in cytokine levels and NK cell activation associated with influenza
Choi et al. Orientia tsutsugamushi subverts dendritic cell functions by escaping from autophagy and impairing their migration
Movita et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct
Loures et al. MyD88 signaling is required for efficient innate and adaptive immune responses to Paracoccidioides brasiliensis infection
Leonardi et al. Akt-Fas to quell aberrant T cell differentiation and apoptosis in Covid-19
Wang et al. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion
Tan et al. Deficiency of canonical wnt/β‐catenin signalling in hepatic dendritic cells triggers autoimmune hepatitis
Moafi et al. Comparison of pro‐inflammatory cytokines of non‐healing and healing cutaneous leishmaniasis
Humphries et al. Pulmonary-resident memory lymphocytes: pivotal orchestrators of local immunity against respiratory infections
Tong et al. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
Urban et al. Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses
Mateo et al. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys
Climent et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8+ T cell responses in HIV-1-infected individuals
Fernandes et al. Paracoccidioides brasiliensis interferes on dendritic cells maturation by inhibiting PGE2 production
Lineburg et al. Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity
Griffin Are T cells helpful for COVID-19: the relationship between response and risk
Prakash et al. Dendritic cells from aged subjects display enhanced inflammatory responses to Chlamydophila pneumoniae
Devalraju et al. Defective expansion and function of memory like natural killer cells in HIV+ individuals with latent tuberculosis infection